Notice: You have clicked on a link which leaves Fresenius Kabi’s website and you will be redirected to a third-party website. Fresenius Kabi makes no representations nor has any supervision or control over the quality, content, reliability, or security of the third-party website, nor shall Fresenius Kabi be liable for its use.

The U.S. Lipid Injectable Emulsion (ILE) Market Leader1

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. Our products are used to help care for critically ill and chronically ill patients in hospitals, long-term care facilities, and at home.

Fresenius Kabi’s innovations in parenteral nutrition (PN)

We are proud of our contributions, which support the advancement of parenteral nutrition products for critically ill and chronically ill patients.

  • Introduced the first lipid PN product for adults in more than 40 years
  • Pioneered the use of fish oil and omega-3s in PN products
  • Brought the benefits of alternative lipid emulsions to market
  • Developed the only pediatric lipid ILE product for PN-associated cholestasis (PNAC) in the U.S.
  • Developed the first and only three-chamber bag for adult PN in the U.S.
Learn more
baby girl sitting

Innovation timeline

2014

Launched the first
3-chambered bag for adult PN

2016

Introduced the first new lipid PN product for adults in 40 years

2018

FDA approves first fish oil ILE for pediatric patients with PNAC

2021

Pipeline products

How can we help?

Contact us

Reference: 1. Data on File; 5/1/20; calculation includes: all ILEs approved in the US.